Group 1 - The article discusses an opportunity for BBNX investors to participate in a fraud investigation led by the Schall Law Firm [1] - The investigation is focused on Beta Bionics, Inc., suggesting potential legal issues surrounding the company [1] - The involvement of a law firm indicates that there may be significant concerns regarding the company's practices or disclosures [1] Group 2 - The announcement highlights the legal landscape surrounding BBNX and its implications for investors [1] - The investigation may uncover critical information that could affect the company's stock performance and investor sentiment [1] - Investors are encouraged to consider their options in light of the ongoing investigation [1]

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday.The Dow traded up 0.38% to 49,453.05 while the NASDAQ climbed 0.66% to 23,635.11. The S&P 500 also rose, gaining, 0.48% to 6,954.85.Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallLeading and Lagging SectorsUtilities shares gained by 1.5% on Friday.In trading on Friday, health care stocks dipped by 0.5%.Top HeadlineThe Univ ...

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Friday.The Dow traded up 0.38% to 49,453.05 while the NASDAQ climbed 0.66% to 23,635.11. The S&P 500 also rose, gaining, 0.48% to 6,954.85.Check This Out: Delta Air Lines Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings CallLeading and Lagging SectorsUtilities shares gained by 1.5% on Friday.In trading on Friday, health care stocks dipped by 0.5%.Top HeadlineThe Univ ...

Diabetes management solutions provider, Beta Bionics Inc. (NASDAQ:BBNX), on Thursday reported preliminary fourth-quarter 2025 results showing strong revenue growth, driven by rapid expansion in its Pharmacy Benefit Plan channel and a growing installed user base for its diabetes management technology.The company said net sales for the quarter are expected to reach at least $32 million, versus the consensus of $28.19 million, representing a year-over-year increase of at least 56%.Sales through the Durable Med ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2026 N/A (Former name or former address, if changed since last report) Beta Bionics, Inc. 11 Hughes (Exact name of registrant as specified in its charter) Irvine, California 92618 (Address of Principal Executive Offices) (Zip Code) (State or Other Jurisdiction of Incorporation) (949) ...

IRVINE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its preliminary, unaudited topline financial results and key metrics for the quarter ended December 31, 2025. Members of the Company’s management team will host in-person meetings in San Francisco, CA from January 12, 2026 through January 14, 2026 to discuss preliminary topline fourth quarter 2025 financial results and key metri ...

Core Viewpoint - Beta Bionics, Inc. plans to pre-release its topline fourth quarter 2025 financial results in early January 2026, highlighting its commitment to transparency and investor engagement [1]. Financial Results - The pre-release will cover key metrics including net sales, new patient starts, and the reimbursement percentage of new patient starts through the pharmacy benefit plan (PBP) channel [2]. Investor Engagement - The management team will hold in-person meetings in San Francisco from January 12 to January 14, 2026, to discuss the topline results, inviting investors to register for these meetings [3]. Company Overview - Beta Bionics is a commercial-stage medical device company focused on developing innovative solutions for insulin-requiring individuals with diabetes, utilizing advanced adaptive closed-loop algorithms [4]. - The iLet Bionic Pancreas is noted as the first FDA-cleared insulin delivery device that autonomously determines insulin doses, aiming to improve health outcomes for a broad population of people with diabetes [4].

Beta Bionics (NasdaqGM:BBNX) FY Conference December 02, 2025 04:30 PM ET Company ParticipantsBlake Beber - Head of Investor RelationsSean Saint - CEOMike Mensinger - Chief Product OfficerConference Call ParticipantsNone - AnalystNoneThe Beta Bionics team with us here today. We've got Mike, who's the Chief Product Officer, is gonna give us full timelines on PatchPump, right now. Sean, who's the CEO, and then Blake that does IR and probably a bunch of other things as well. So thanks so much for making the lon ...

Summary of Beta Bionics Conference Call Company Overview - **Company**: Beta Bionics (NasdaqGM: BBNX) - **Event**: 2025 Conference on November 18, 2025 Key Points Industry and Market Position - Beta Bionics is experiencing growth in both starts and revenue, with a focus on the insulin pump market [3][4] - The company is competing in a highly competitive environment, particularly against a tubeless pump competitor [7][27] Product Differentiation and Success Factors - The iLet insulin pump has a unique design and algorithm that differentiates it from competitors, leading to commercial success [3][4] - Pharmacy reimbursement has exceeded expectations, generating approximately $450 per month in recurring revenue and facilitating easier prescriptions for doctors [4][5] - The ease of use of the iLet pump is a significant selling point, making it easier for patients to start and maintain their treatment [8][9][12] Clinical Outcomes - The clinical outcomes of the iLet are reported to be as good or better than other systems on the market, with significant improvements in patient A1C levels [9][28] - The company emphasizes the importance of patient lifestyle improvements alongside clinical outcomes, which are often prioritized by users [13] Prescriber Profile and Market Strategy - Ideal prescribers for the iLet are open-minded doctors who prioritize patient outcomes and are willing to adopt new technologies [16][17] - The sales strategy is data-driven, focusing on demonstrating the product's effectiveness through real-time data access for healthcare providers [19] Market Share and Growth Projections - Beta Bionics estimates capturing approximately 11% of new patient starts in the U.S. market, with potential for growth as the sales force expands [23] - The company aims to increase its territories from 63 to around 120 in the long term, with ongoing investments in sales coverage [25] Future Product Development - Beta Bionics is working on a patch pump, targeting commercialization by the end of 2027, with ongoing manufacturing and regulatory preparations [33][40] - The patch pump will be pharmacy-only, leveraging existing pharmacy reimbursement agreements to facilitate market entry [45][47] Regulatory and Compliance Updates - The company is addressing a remediation effort for approximately 34,000 cases, expected to be completed by June 2026 [66] - Ongoing communication with the FDA is in place, with updates provided every 45 days regarding compliance matters [64][66] Conclusion - Beta Bionics is positioned for growth in the insulin pump market, with a focus on product differentiation, ease of use, and strong clinical outcomes. The company is actively preparing for future product launches while managing regulatory compliance effectively.

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Cambium Networks Corporation (CMBM) has seen a remarkable increase of 306%, trading at $2.51 [3] - Teradyne, Inc. (TER) is up 21%, currently priced at $176.00 [3] - Bloom Energy Corporation (BE) has risen by 18%, trading at $134.50 [3] - Jamf Holding Corp. (JAMF) is up 15%, with a price of $12.85 [3] - CSG Systems International, Inc. (CSGS) has increased by 14%, trading at $79.00 [3] - Olympic Steel, Inc. (ZEUS) is also up 14%, currently priced at $34.20 [3] - Beta Bionics, Inc. (BBNX) has risen by 12%, trading at $27.20 [3] - Sonim Technologies, Inc. (SONM) is up 10%, currently priced at $12.49 [3] - Canadian Solar Inc. (CSIQ) has increased by 9%, trading at $16.67 [3] - Interlink Electronics, Inc. (LINK) is also up 9%, currently priced at $6.85 [3] Premarket Losers - Stride, Inc. (LRN) has experienced a significant decline of 41%, trading at $89.44 [4] - Varonis Systems, Inc. (VRNS) is down 29%, currently priced at $44.71 [4] - Akebia Therapeutics, Inc. (AKBA) has decreased by 26%, trading at $2.26 [4] - Avantor, Inc. (AVTR) is down 17%, currently priced at $12.40 [4] - GlucoTrack, Inc. (GCTK) has seen a decline of 13%, trading at $6.29 [4] - Tigo Energy, Inc. (TYGO) is down 13%, currently priced at $2.20 [4] - Generac Holdings Inc. (GNRC) has decreased by 9%, trading at $172.00 [4] - Polar Power, Inc. (POLA) is down 8%, currently priced at $3.71 [4] - Caesars Entertainment, Inc. (CZR) has seen a decline of 7%, trading at $20.50 [4] - Anteris Technologies Global Corp. (AVR) is also down 7%, currently priced at $4.46 [4]